Fund reports
Review manager quality, strategy, portfolio evidence, pacing and downside.
Rupeia publishes allocator-side research on venture capital, private equity, private credit, fund comparisons, manager quality, portfolio construction, secondaries and other long-duration private-market decisions. The research is designed for founders, families, NRIs, family offices, corporate VC teams and institutions that need clearer questions before deeper diligence.
Review manager quality, strategy, portfolio evidence, pacing and downside.
Separate brand strength, access and narrative from actual structural differences.
Study entry price, liquidity, ownership transfer, risks and missing evidence.
Venture Capital / Early-Stage Fintech | Fund Report
An early-stage India fintech VC report comparing Stellaris, Arkam, 3one4 and Blume on named fintech evidence, underwriting quality and whether the firms offer genuine fintech-heavy exposure rather than generic seed-stage diversification with a light sector tilt.
Read the report contextVenture Capital / Global Fintech | Fund Report
A comparison of global fintech specialist investors including QED, Quona, Flourish and Ribbit to test whether India and emerging-market underwriting is truly embedded in the franchise or treated as a satellite geography behind a broader global fintech narrative.
Read the report contextVenture Capital / India Fintech | Fund Report
A fund report comparing platform VC firms with India fintech practices and testing whether large multi-stage brands such as Elevation, Bessemer India, Accel India and Peak XV actually maintain resourced fintech underwriting or simply label fintech as one line item in a broad generalist mandate.
Read the report contextFintech / Payments / Secondary | Pre-IPO Secondary
A secondary review on PhonePe focused on the General Atlantic transaction, OFS-only IPO structure, seller-versus-buyer signal, payments-market concentration and whether public investors are being asked to absorb informed shareholder exits at full price.
Read the report contextQuick Commerce / Pre-IPO Secondary | Pre-IPO Secondary
A pre-IPO secondary note on Zepto covering valuation compression risk, Indian family office buying rounds, domestic ownership positioning before IPO and whether the growth story is strong enough to justify secondary entry ahead of public-market price discovery.
Read the report contextPrivate Credit / Category II AIF | Fund Report
A performing-credit comparison across InCred ICOF-III, Sundaram PCOF-I, MO India Credit Excellence Fund I and Northern Arc Growth Fund focused on yield quality, collateral strength, repayment visibility and real downside before treating headline credit IRR as comparable.
Read the report contextIndia Fintech / Payments Infrastructure | Pre-IPO Secondary
Razorpay's IPO is coming at a 33-37% cut to its last private valuation, which means every secondary buyer today is deciding whether the IPO price is a floor for long-term entry or the ceiling before public-market reality resets expectations
Read the report contextIndia Venture Capital / Secondaries | Portfolio Secondary / LP Context
Peak XV returned $7B+ to LPs and saw five IPOs in six weeks, yet its new fund is 54% smaller than the 2021 vintage - that combination makes this the clearest live test of whether India VC secondaries reflect disciplined DPI or hidden franchise stress
Read the report contextB2B Commerce / SME Lending | Pre-IPO Secondary
OfBusiness is targeting a $6-9B IPO while Z47 is trying to sell a $200M stake at a $5B mark just after FY25 PAT fell 67% - the real question is whether the buyer is being asked to fund the seller's exit before the profit story is understood
Read the report contextVenture Capital (Early-to-Growth Stage) | Seed to Series B
Z47 (formerly Matrix Partners India) raised its first fully independent fund after separating from its US parent - making it simultaneously the most experienced early-stage team in India and the most structurally untested fund vehicle in the market
Read the report contextPrivate Credit / Performing Credit | Growth to Pre-IPO
Vivriti's Debt Backed Fund III and True North's PCRIF are both performing credit instruments - but they take structurally opposite bets on the same Indian credit market; choosing the wrong one for a client's risk profile is not a 1% difference in return, it is a 400-600 bps difference
Read the report contextSpaceTech / Launch Vehicles | Series C
Skyroot is India's only private company with an orbital-class rocket at the Sriharikota launchpad - and its FY23 and FY24 'revenues' cited in virtually every investor deck were entirely interest income on raised capital, not a single rupee of commercial revenue
Read the report contextSpace / Earth Observation AI | Series A+
India's three largest private banks - ICICI, HDFC and Kotak - invested in SatSure not for financial return but because they use its satellite-based crop intelligence to underwrite agricultural loans; banks investing in their own vendor is the strongest possible commercial validation signal
Read the report contextVenture Capital (Multi-Stage) | Seed to Series D
Peak XV's Ashish Agrawal - the partner who sourced Groww at what became a ~62x MOIC - departed in January 2026 amid a reported carry dispute; this is a live, unresolved key-person risk inside India's most prominent VC brand
Read the report contextVenture Capital (Early-to-Growth Stage) | Seed to Series B
Nexus Venture Partners has backed more Rs 1,000 Cr+ exits per fund than any India-dedicated VC of its vintage - yet it remains structurally inaccessible to all but the largest institutional LPs
Read the report contextPrivate Equity (Growth & Buyout) | Growth to Pre-IPO
Multiples PE is raising Fund V before Fund IV has fully exited - a pre-launch signal that LP demand is so strong that the fund doesn't need to wait for realised DPI to begin its next raise
Read the report contextVenture Debt / Structured Credit | Series A to Series C
Venture debt from Trifecta, Stride, Alteria and InnoVen sits senior to equity in the capital stack - meaning it gets paid back first in any exit or liquidation - yet almost no Indian family office has ever made a single rupee allocation to this asset class
Read the report contextVenture Capital (Seed & Early Stage) | Seed to Series A
Blume, Kae, Stellaris and 3one4 have collectively returned more capital per rupee deployed than most Category II AIFs - yet Indian HNIs almost never access them as LPs
Read the report contextPrivate Credit / Alternate Fixed Income | Growth to Pre-IPO
Private credit in India (Edelweiss, Kotak, Avendus) is generating 16-22% net IRRs with sub-3% default rates - returns that listed equity has not consistently delivered in a decade, yet 90% of family offices remain entirely unallocated
Read the report contextPrivate Equity (Growth) | Series D to IPO
Advent, General Atlantic, Warburg Pincus and KKR all deploy into India - but fewer than 12 Indian family offices have ever received a co-investment offer from any of them
Read the report contextVenture Capital (DeepTech) | Seed to Series B
India's deeptech VC ecosystem (Speciale, Shastra, Ankur, pi Ventures) collectively manages less capital than a single mid-sized US sector fund - yet they are the only pools backing India's defence, space, and semiconductor startups
Read the report contextDeep Tech / Advanced Manufacturing | Series B
Two engineering students built India's first 5-axis precision CNC machine from a dorm room with Rs 1.5 lakh because they couldn't afford to buy one at Rs 6-7 lakh - that same machine architecture is now valued at Rs 1,470 crore
Read the report contextPrivate Equity (Growth & Buyout) | Growth to Pre-IPO
ChrysCapital Fund X raised $2.2B - the largest-ever India-focused PE fund - in just 6 months, while the global PE industry average is 24+ months; that 18-month gap is the most powerful trust signal in Indian private equity
Read the report contextSpaceTech / Satellite Propulsion | Pre-Series B
The co-lead investor from Bellatrix's Series A (Steadview Capital) did NOT participate in the very next round - a fact buried in every press release and the single most important unexplained signal in the deal
Read the report contextVenture Capital (Early-to-Growth Stage) | Seed to Series B
Accel India has backed more Indian unicorns per dollar deployed than any other VC firm - yet most Indian family offices have never been offered a direct LP seat
Read the report contextPrecision Oncology / Clinico-Genomic AI | Series B
Non-Caucasian patients are 70% of global cancer cases but less than 5% of genomic research data - 4baseCare is the only company building the database that corrects this, and its MSK Memorial Sloan Kettering validation is the highest possible clinical endorsement outside a clinical trial
Read the report context